{
    "clinical_study": {
        "@rank": "135991", 
        "arm_group": [
            {
                "arm_group_label": "E2006 2.5 mg", 
                "arm_group_type": "Other"
            }, 
            {
                "arm_group_label": "E2006 10mg", 
                "arm_group_type": "Other"
            }, 
            {
                "arm_group_label": "E2006 25 mg", 
                "arm_group_type": "Other"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a single-center, open-label, randomized crossover study being conducted in three\n      cohorts of healthy adult subjects. Approximately 36 subjects will be randomized to one of\n      three cohorts (approximately 12 subjects per cohort) and they will receive both a single\n      dose of E2006 in capsule formulation and a single dose of E2006 in tablet formulation, in\n      random sequence, at a 1:1 ratio. The doses to be tested will be 2.5 mg, 10 mg, and 25 mg."
        }, 
        "brief_title": "Open-Label Study of Bioavailability of E2006 Tablet Versus Capsule Formulations", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Insomnia", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion:\n\n          -  Healthy males or females,\n\n          -  ages 18 to 55 years\n\n          -  Body mass index (BMI) &gt;\n\n          -  18 and  32 kg/m2 at Screening\n\n        Exclusion:\n\n          -  Female subjects who are nursing\n\n          -  Subjects with a history of gastrointestinal surgery (hepatectomy, nephrectomy,\n             digestive organ resection, etc.) that may affect PK profiles of E2006\n\n          -  Subjects with a known history of clinically significant drug or food allergies\n\n          -  Subjects with a known allergy or hypersensitivity to capsule or tablet ingredients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01673880", 
            "org_study_id": "E2006-A001-005"
        }, 
        "intervention": {
            "arm_group_label": [
                "E2006 2.5 mg", 
                "E2006 10mg", 
                "E2006 25 mg"
            ], 
            "description": "2.5 mg, 10 mg, and 25 mg E2006 tablets", 
            "intervention_name": "E2006", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 20, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Austin", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78704"
                }, 
                "name": "PPD Development, LLC"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Single-center, Open-label, Randomized, Multi-cohort, Crossover Study of Relative Bioavailability of Tablet Versus Capsule Formulation of E2006 in Healthy Adult Subjects", 
        "overall_official": {
            "affiliation": "PPD", 
            "last_name": "Aziz Laurent", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Plasma concentrations of E2006 of tablet vs. capsule formulations", 
            "safety_issue": "No", 
            "time_frame": "up to 336 hours post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01673880"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Incidence of adverse events (AEs)", 
            "safety_issue": "Yes", 
            "time_frame": "36 days"
        }, 
        "source": "Eisai Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eisai Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}